. This meeting provided an international platform for physicians and investigators active in the research and utilization of pediatric Allo-SCT in children and adolescents with malignant and non-malignant disease (NMD), to share information and develop future collaborative strategies. The primary objectives of the conference included: (1) to present advances in Allo-SCT in pediatric ALL and novel pre and post-transplant immunotherapy; (2) to highlight new strategies in alternative allogeneic stem cell donor sources for children and adolescents with non-malignant hematological disorders; (3) to discuss timing of immune reconstitution after Allo-SCT and methods of facilitating more rapid recovery of immunity; (4) to identify strategies of utilizing Allo-SCT in pediatric myeloproliferative disorders; (5) to develop diagnostic and therapeutic approaches to hematological complications post pediatric Allo-SCT; (6) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders; and (7) to discuss optimizing drug therapy in pediatric recipients of Allo-SCT. This paper will provide a brief overview of the conference.
INTRODUCTION
The inaugural meeting of 'New Frontiers in Pediatric Allogeneic Stem Cell Transplantation' organized by the Pediatric Blood and Transplant Consortium (PBMTC) was held in Miami, Florida on April 24, 2013 at the American Society of Pediatric Hematology and Oncology Annual Meeting. This meeting provided an international platform for physicians and investigators active in the research and utilization of pediatric Allo-SCT in children and adolescents with malignant and NMDs, to communicate, share information and develop future collaborative strategies. The primary objectives of the conference included: (1) to present advances in Allo-SCT in pediatric ALL with a focus on minimal residual disease (MRD), eligibility and novel pre and post-transplant immunotherapy; (2) to highlight new strategies in alternative Allo-SCT donor sources for children and adolescents with non-malignant hematological disorders; (3) to discuss the timing of immune reconstitution after Allo-SCT and methods of facilitating more rapid recovery of immunity; (4) to discuss optimizing drug therapy in pediatric recipients of Allo-SCT; (5) to identify strategies of utilizing Allo-SCT in pediatric myeloproliferative disorders; (6) to develop diagnostic and therapeutic approaches to hematological complications post pediatric Allo-SCT; and (7) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders. A brief overview of the meeting is presented below.
The first plenary session addressed critical issues including MRD, cytogenetics and immunotherapy during Allo-SCT in children and adolescents with ALL. First, the importance of MRD pre and postAllo-SCT in pediatric ALL was reviewed. For all studies, MRD was measured on BM aspirates and performed using six-color flow cytometry. 1 Bader et al. 2 has previously demonstrated that MRD before Allo-SCT was shown to predict outcome in children with relapsed ALL who received Allo-SCT in ⩾ second complete remission (CR2). Probability of event-free survival (pEFS) and cumulative incidence of relapse (CIR) in patients with MRD ⩾ 10 −4 leukemic cells was 0.27 and 0.57 compared with 0.60 and 0.13 in patients with MRD less than 10 −4 leukemic cells (EFS, P = 0.004; CIR, P o0.001).
2 Intermediate-risk patients with MRD ⩾ 10
leukemic cells had a pEFS of 0.20 and CIR of 0.73, whereas patients with MRD o 10 −4 leukemic cells had a pEFS of 0.68 and CIR of 0.09 (EFS, P = 0.020; CIR, P o0.001).
2 High-risk patients ⩾ CR3 who received transplantation with an MRD load o 10 −4 leukemic cells showed a pEFS and CRI of 0.53 and 0.18, respectively. 2 In contrast, pEFS and CRI were 0.30 and 0.50 in patients who received transplantation with an MRD load of ⩾ 10 −4 leukemic cells. 2 Multivariate Cox regression analysis revealed MRD as the only independent parameter predictive for EFS (P = 0.006) 2 ( Figure 1 ). In addition, Leung et al. 3 demonstrated in children with very-high-risk ALL or AML who received an Allo-SCT and that higher MRD levels at the time of Allo-SCT predicted a poorer survival and that MRD was an independent prognostic factor in a multivariate analysis.
There are a few subtypes of ALL where strong consideration should be made for allotransplant in CR1 in whom the outcomes with chemotherapy alone are dismal.
Historically, these have included BCR/ABL, hypodiploid ALL and MLL rearrangements. However, with the recent results from the Children's Oncology Group (COG) using tyrosine kinase inhibitors (TKIs) versus Allo-SCT in patients with Philadelphia chromosomepositive ALL provide interesting insights into the role of Allo-SCT in this disease. 4 Updates from COG study AALL0031 revealed no significant differences (P = 0.93) in the estimates of EFS for patients with Philadelphia chromosome-positive ALL enrolled on cohort 5 receiving imatinib (EFS, 84 ± 7%) versus matched sibling donor Allo-SCT (EFS, 77 ± 12%) versus matched unrelated donor Allo-SCT (EFS, 83 ± 15%). 4 Hypodiploid ALL is another high-risk feature in childhood ALL, which has been an indication for Allo-SCT in the past. 5, 6 Importantly, a high rate of TP53 mutations has been identified in patients with low hypodiploid ALL (32 to 39 chromosomes). Approximately 45% of these patients were subsequently found to have germline events, thus firmly establishing this subtype of childhood ALL within the Li-Fraumeni syndrome. Slow response to induction therapy has been the single most important risk factor for relapse in children and adolescents with ALL and are an indication for Allo-SCT in the past. 6 Many centers pursue Allo-SCT early for patients with frank induction failure (day 29 BM with >25% lymphoblasts) after reinduction strategies. 6 Novel approaches to preventing relapse were discussed and included pretransplant conditioning, post-transplant immunosuppression, donor lymphocyte infusion and novel agents including immunotherapeutic approaches. Myeloablative transplants for ALL that include TBI of 1200 cGY or greater have an improved survival benefit compared with non-TBI-containing regimens. 7 The leukemia-free survival is approximately 15-33% higher in patients who received TBI-containing regimens compared with those who received non-TBI-containing regimens ( Figure 2 ). [8] [9] [10] Other strategies to prevent relapse include utilizing lower doses of CYA 11 and a rapid taper of CYA and/or donor lymphocyte infusion for increasing mixed chimerism post transplant. 12 An overview of upcoming novel agents and immunotherapeutic approaches to reduce MRD pretransplant was performed, which included moxetumomab pasudotox (anti CD22-immunotoxin) for childhood ALL, which is currently in Phase I − II trials at the NCI. 13, 14 Anti-CD19 bispecific T-cell engager Blinatumomab has shown promising results in a Phase II adult trial in MRD eradication and is currently under investigation in pediatric trials. 15, 16 Other novel therapies include genetically engineered cells to target ALL -chimeric antigen receptor transduced T cells, which are also currently in early phase trials including CD19 and CD22 chimeric antigen receptors and thus far, the early results are encouraging. 17 The second session entitled 'Alternative Allogeneic Donor Stem Sources in Children with Non-Malignant Hematological Diseases' discussed alternative allografts including matched unrelated donor, umbilical cord blood (UCB) and haploidentical transplantation. The donor chosen for allogeneic transplantation is dependent on a multitude of factors including degree of mismatch, the cell dose if UCB is utilized and timing of transplant. The types of diseases that are transplanted include hemoglobinopathies, immune deficiencies, BM failure syndromes and Figure 2 . Probability of leukemia-free survival. A indicates chemotherapy recipients after an early first relapse; B, transplant recipients with TBI regimens after an early first relapse; C, transplant recipients with non-TBI regimens after an early first relapse; D, chemotherapy recipients after late first relapse; E, transplant recipients with TBI regimens after late first relapse; and F, transplant recipients with non-TBI regimens after late first relapse. From Eapen et al.
metabolic diseases. Cairo et al. 18 reported on the experience of using unrelated UCB for non-malignant diseases (NMD). The majority of the preparative regimens were BU based with 30% utilizing fludarabine and 84% utilizing an anti-T-cell therapy. The role of HLA mismatching was abrogated by increasing cell dose of the UCB. Patients given a higher cell dose >3. 5 10 7 /kg even with 0-3 HLA disparities had a higher probability of engraftment compared with those given lower cell dose with the same disparities ( Figure 3 ). Horan et al. 19 analyzed data from 663 unrelated marrow and PBSC transplants performed from 1995 to 2007 for the treatment of NMD. Transplantation from a donor mismatched at the HLA-A, -B, -C or -DRB1, but not -DQB1 or -DPB1, loci was associated with higher mortality in multivariate analyses (P = 0.002). 19 HLA mismatches were not associated with acute or chronic GVHD, but were strongly associated with graft failure. The authors concluded that patients with NMD should receive transplants from allele matched (8/8) donors if possible. 19 However, improvements in BMT supportive care, minimizing preparative regimen intensity and toxicity, and novel posttransplant immunosuppressive regimens are making alternative donor transplants a safer option. Finally, antibodies directed against donor-disparate HLA antigens increase graft failure risk, which is particularly important in this population of patients with NMDs. 20, 21 Alternative allografts in patients with hemoglobinopathies were discussed and Pietro Sodani reviewed their institutional experience with haploidentical SCT and CD34 selection using the CliniMACS device (Miltenyi Biotec, Cambridge, MA, USA) in patients with thalassemia and sickle cell disease. Sodani et al. 22 added hydroxyurea, azathioprine and fludarabine to their traditional BU and CY preparative regimen for children with class 3 thalassemia. This resulted in a survival of 93% and a decreased rejection from 30 to 8%. 22 To extend transplantation to all patients who do not have a well-matched unrelated donor, haploidentical transplant has been performed in children with thalassemia. 23 Twenty-two patients underwent transplantation with a 90% survival at 5 years; however, they experienced a 27% rejection rate. This study demonstrated that this approach is feasible and has been recently applied to children with sickle cell disease. 24 Clinical trials in Fanconi anemia have focused on obtaining adequate engraftment with less collateral damage. Wagner et al. 25 reported on a fludarabine-based regimen in Fanconi anemia. He found the day-100 mortality rate was significantly higher after non-fludarabine-containing regimens compared with fludarabinecontaining regimens (65% vs 24%, respectively; P o 0.001). 25 Corresponding the 3-year adjusted overall survival rates were 52 vs 13% (P o 0.001). 25 In addition, mortality was higher in recipients who were older (>10 years), CMV seropositive and who received >20 blood product transfusions before Allo-SCT. 25 Immune reconstitution after Allo-SCT in pediatric recipients was reviewed by allogeneic donor source during the third plenary session. The quantity and quality of immune reconstitution is correlated with long-term clinical outcomes: survival, presence of GVHD, infections and relapse rate. Bartelink et al. 26 compared immune reconstitution by various graft sources in pediatric recipients. The nature and speed of T cell, B cell and natural killer (NK) cell reconstitution were highly dependent on the cell source. In the first 90 days after hematopoietic SCT, faster B cell and NK cell reconstitution and delayed T-cell reconstitution were shown in unrelated cord blood recipients compared with matched sibling BM and unrelated BM recipients. 26 A more rapid and sustained CD4+ cell count reflected by higher CD4+ area under the curve (AUC) correlated with reduced mortality. Renard et al. reported on the post-transplant lymphocyte subset recovery of children treated with unrelated UCB transplant or unrelated BMT for malignant and NMD. 27 NK cells recovered first in a similar time frame for both graft sources. B cells recovered quicker in unrelated UCB transplant, compared with unrelated BMT.
Outcomes after Allo-SCT have steadily improved over the past several decades, and much of this improvement is due to refinement of strategies to prevent and treat infectious complications. 28, 29 Effective prophylaxis requires information regarding individual patient risk of developing specific opportunistic infections, as well as the availability of chemoprophylaxis agents that can either prevent development or progression of infection. [30] [31] [32] [33] [34] [35] The profound deficit in lymphoid immunity imposed by Allo-SCT increases the risk of both episodic viral infections and reactivation of latent viruses. Clinically important latent viruses include mostly herpes viruses (CMV, EBV, Human Herpes Virus 6, HSV and VZV), with CMV being the most commonly seen after Allo-SCT. Allo-SCT recipients are also vulnerable to invasive fungal infections both during the pre-engraftment neutropenic period (allogeneic/autologous) and post-engraftment due to T-cell lymphopenia (allogeneic). 36 Revaccination strategies post Allo-SCT in pediatric recipients were also addressed in this session. In 2009, the CDC and Center for International Blood and Marrow Transplant Research published guidelines with substantial new recommendations. 37 These included inactivated vaccines to start as early as 6 months post hematopoietic SCT, administering inactivated vaccines despite presence of GVHD, pneumococcal vaccine to start as early as 3 months post HCT and varicella vaccine changed from contraindicated to optional (Table 1) . 37 Optimizing drug therapy in pediatric Allo-SCT was discussed during plenary session four with a focus on pharmacokinetics/ pharmacodynamics in pediatric Allo-SCT recipients. Practice patterns of dosing of IV busulfan (BU) were reviewed. In 729 children who underwent therapeutic drug monitoring at Seattle Cancer Care Alliance Busulfan Pharmacokinetics Laboratory, the initial BU dose achieved the target exposure in only 24.3% of children. 38 Pediatric Allo-SCT recipients receiving IV BU Q12H achieved a target AUC 60% of the time. 39 Pediatric Allo-SCT recipient results indicates that daily IV BU (N = 221) has similar pharmacokinetics as every12 h (N = 20) and every 6 h (N = 162) administration. 40 Multi-institutional pharmacokinetic studies are needed to improve dosing in pediatric Allo-SCT patients.
Therapeutic drug monitoring of mycophenolate mofetil in pediatric Allo-SCT recipients was discussed. Mycophenolic acid (MPA) exposure is low in Allo-SCT relative to organ transplant recipients possibly attributed to loss of enterohepatic recycling due to gut decontamination, destruction of absorptive capacity, enhanced glucuronidation or altered drug transport. This results in high interpatient variability in MPA exposure. IV dosing achieves higher unbound MPA exposures than oral. Total MPA trough ⩾ 1 mcg/mL was associated with better engraftment and less acute GVHD. 41, 42 Unbound AUC 0-12>300 ng hr/mL was Pediatric Allo-SCT JM Talano et al.
associated with less acute GVHD (cumulative AUC of 600 ng hr/mL in 24 h period). Proposed MPA target concentrations were achieved in 50% or less of nonmyeloablative Allo-SCT recipients receiving mycophenolate mofetil 2g/day. During plenary session 5, the role of allografting in children with pediatric myeloproliferative disorders was discussed. The role of Allo-SCT in juvenile myelomonocytic leukemia was presented and specifically the results of a recent North American protocol which evaluated tipifarnib, afarnesyltransferase inhibitor in a phase 2 window before Allo-SCT. The results thus far show a trend toward inferior survival in those patients who received tipifarnib compared with the controls. Currently, there is a new North American protocol underway that is randomizing the conditioning regimen before transplantation comparing BU and fludarabine versus BU, CY and melphalan (COG ASCT1221).
CML in children was discussed addressing the question: with the advent of TKIs, should pediatric patients undergo Allo-SCT? Millot et al. 43 conducted a clinical trial in children with newly diagnosed CML in chronic phase who received daily imatinib 260 mg/m 2 . Progression-free survival, responses and tolerance were evaluated. With a median follow-up of 31 months, the estimated progression-free survival at 36 months was 98% (95% confidence interval, 85 to 100%). A complete hematologic response was achieved in 98% of the patients. The rates of complete cytogenetic response and major molecular response were 61 and 31% at 12 months, respectively. During followup, complete cytogenetic response and major molecular response were achieved in 36 children (77%) and 25 children (57%), respectively. Overall, 30% of the patients discontinued imatinib, mainly because of unsatisfactory response. The most common adverse events were neutropenia and musculoskeletal events. So the question is which option should we offer patients, long-term cure with Allo-SCT or lifelong TKI? A reasonable approach is first to enroll children and adolescents in open CML protocols. If the patient is in chronic phase-starting with hydroxyurea and a TKI and following closely BCR/ABL by cytogenetics and PCR is a reasonable first approach. 44 However, if a patient is in accelerated phase or blast crisis, develops resistance to TKI and/or fails to achieve cytogenetic remission, then proceeding to Allo-SCT is a reasonable choice. As children and adolescents are treated for longer periods of time with TKIs, it has become clear that toxicities may make long-term TKI therapy less attractive compared with Allo-SCT. Reduced-intensity conditioning and Allo-SCT have significantly less transplant-related morbidity compared with myeloablative conditioning, 36, 45 whereas prolonged TKIs may cause growth failure, hepatic and cardiac complications. Therefore, randomized international trials are urgently needed to evaluate the best therapies for pediatric CML.
The role of allografting in myelodysplastic syndrome (MDS) in children was also discussed. MDS is a rare disorder affecting 4/million children/year and represents a heterogeneous group of clonal hematopoietic stem cell disorders. The disease is characterized by cytopenias and ineffective and dysplastic hematopoiesis, which have varying propensities to leukemic transformation. MDS can be caused by chemo or radiation therapy. Strahm et al. 46 reviewed the Allo-SCT experience in children with MDS. Thirty-nine children were transplanted from matched sibling donor, whereas 58 were given the allograft from a matched unrelated donor (n = 57) or alternative family donor (n = 1). With a median follow-up of 3.9 years, the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality and relapse is 21% each. Age at Allo-SCT >12 years, interval between diagnosis and Allo-SCT >4 months and occurrence of acute GVHD or extensive chronic GVHD were associated with increased transplantation-related mortality. The risk of relapse increased with more advanced disease.
Hematological complications after allografting in pediatric recipients were discussed in Plenary Session 6. Autoimmune hemolytic anemia (AIHA) can occur in 2-20% post-Allo-SCT. Sanz et al. 47 reviewed 272 patients and found the 3-year cumulative incidence of AIHA was 4.44%. Horn et al. 48 reported a high incidence (19.5%) of AIHA in 41 patients with SCID who underwent a T cell-depleted haploidentical transplant. Other than infections, AIHA was the most common post-transplant complication in this patient cohort. Delayed reconstitution of T-cell immunity, due to T-cell depletion, immunosuppressive conditioning and CYA, as well as paucity of regulatory T cells, were possible causes for the occurrence of AIHA. The use of rituximab has been reported in case reports as effective therapy. Other treatments include steroids, intravenous Ig, splenectomy and other immunosuppressant drugs. For patients who are resistant to these therapies, recent publications have suggested the use of bortezomib. 49, 50 However, future prospective trials are needed to further evaluate this treatment in this setting.
Thrombotic microangiopathy (TMA) post Allo-SCT was also discussed. This is an under-recognized entity and occurs in approximately 20% of Allo-SCT patients. 51 TMA is associated with high-dose chemotherapy, radiation, GVHD, Allo-SCT, calcineurin inhibitors and infection. There have been reports of a higher incidence of AIHA after UCB transplant compared with other allo donor sources. 52 Mortality can be 60-90% in severe disease. 53 Previous studies have reported poor response rates to therapeutic plasma exchange for TMA; however, recently Jodele et al. 54 has recently published a case series involving ten patients suggesting that early initiation of therapeutic plasma exchange might be beneficial even in patients with multiorgan failure due to TA-TMA. New diagnostic biomarkers are needed and research is currently ongoing.
Finally, in the evening plenary session seven, UCB graft engineering was discussed. In cord blood transplantation, the continued challenges are related to delayed neutrophil and platelet engraftment 55 as well as a higher incidence of primary graft failure compared with other sources of allogeneic stem cells (Figure 4 ). New strategies to enhance hematopoietic recovery will potentially reduce the risk of transplantation-related mortality. To overcome the cell dose barrier in unrelated UCB transplant, multiple strategies are being pursued, which include double cord blood transplant, infusion of a haploidentical graft simultaneously with a cord and ex vivo cord blood expansion methods. One method of ex vivo expansion manipulates signaling pathways known to influence hematopoietic stem cell fate using engineered Notch ligands to induce endogenous Notch signaling of CD34+ CB cells. Hematopoietic stem cells are isolated and cultured in the presence of an engineered notch ligand form produced as clinical grade product. The goal of this work is to generate progenitor cells capable of providing rapid short term myeloid engraftment, in order to overcome the delay in hematopoietic recovery in recipients of unrelated UCB transplant. In a current ongoing trial using the engineered product, the median time to engraftment is significantly reduced in patients receiving the manipulated graft product compared with controls double UCB (11 days versus 25 days, Pp0.0001).
56
Other strategies to improve engraftment and reduce primary graft failure were discussed including third party facilitator cellular therapy: CB Mesenchymal Precursor Cells (Mesoblast), CB HSCs (Stem Ex) and Human Placental Derived Stem Cells. Mesenchymal precursor cells may provide cellular and extracellular components of the stem cell 'niche' absent in current liquid culture protocols, eliminating the need for positive selection and potentially improving expansion and engraftment. De Lima et al. 57 reported engraftment results in 31 adults with hematologic cancers who received transplants of two cord-blood units, one of which contained cord blood that was expanded ex vivo in co-cultures with allogeneic mesenchymal stromal cells. In patients in whom engraftment occurred, the median time to neutrophil engraftment was 15 days in the recipients of expanded cord blood, as compared with 24 days in controls who received unmanipulated cord blood only (Po 0.001). There is currently a phase 3 randomized multicenter trial underway to evaluate the efficacy and safety of UCB cells expanded ex vivo with mesenchymal precursor cells for hematopoietic recovery in patients with hematologic malignancies after myeloablative conditioning.
Finally, utilizing NK cells to enhance the immune system and exploit their antitumor potential was highlighted. NK cells kill tumor targets through multiple pathways including granule exocytosis and a death receptor pathway. Donor-versus-recipient NK cell alloreactivity derives from a mismatch between donor NK clones, carrying specific inhibitory receptors for self MHC class I molecules, and MHC class I ligands on recipient cells. When faced with mismatched allogeneic targets, these donor NK clones sense the missing expression of self HLA class I alleles and mediate killing. Transplantation from NK alloreactive haploidentical donors has been shown to reduce AML relapse and improve engraftment with a low incidence GVHD. 58 Ex vivo expansion of NK cells can also be performed and then reinfused into patients post allotransplantation. Liu et al. 59 used a strategy of adoptive transfer of NK cells combined with tumor-specific monoclonal Abs against malignancies. Large numbers of activated NK cells were grown ex vivo from PBMC of children with high-risk neuroblastoma using artificial APCs. Multiple clinical trials utilizing NK cells in both the allogeneic transplant setting and the non-transplant setting are currently under investigation.
In summary, this conference on 'New Frontiers in Pediatric Allogeneic Stem Cell Transplantation' provided a thorough review of the past, present and future strategies and developments in this burgeoning field, and we look forward to this becoming an annual event. A follow-up manuscript will provide a more in depth review of each of the seven plenary sessions at this historical inaugural symposium. 
